Versant Capital Management, Inc Neurocrine Biosciences Inc Transaction History
Versant Capital Management, Inc
- $710 Million
- Q3 2025
A detailed history of Versant Capital Management, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 518 shares of NBIX stock, worth $74,182. This represents 0.01% of its overall portfolio holdings.
Number of Shares
518
Previous 517
0.19%
Holding current value
$74,182
Previous $64,000
12.5%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding NBIX
# of Institutions
683Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.03 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.4 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$797 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$640 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$442 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...